Beyond the headlines: Making sense of ASH now

Tomorrow: December 10, 2025 | 11:30 AM – 1:05 PM ET

ASH kicks off tomorrow, and the stakes couldn't be higher.

As hematology data begin to roll in, drug developers and investors will be parsing every readout for signals that could reshape R&D priorities and capital-allocation decisions. With skeptical markets watching closely and lifelines riding on CGT outcomes, understanding what the data actually mean — not just what the headlines say — will be critical.

Join us as leading researchers and industry experts — including Arcellx CEO Rami Elghandour and Kite Executive Vice President Cindy Perettie — unpack the most consequential blood cancer readouts of the year. This is your last chance to secure your spot.

SPONSORED BY